Pharma launch plans often overlook a critical driver of success: a formal insights strategy.
Johnson & Johnson’s Medical Affairs team is transforming strategy with data-driven insights, moving beyond traditional approaches to identify key opinion leaders, improve advisory board diversity, and enhance patient journey mapping. With H1’s analytics, they are shifting from quantity to quality in engagements, advancing health equity, and leveraging AI for smarter decision-making.
Medical Affairs is uniquely positioned as the only department capable of impacting the Enterprise Commercialization Process (ECP) at every stage, from the initial product concept through the entire commercialization effort.
Addressing the critical importance of integrating robust scientific understanding into the commercial journey, pinpointing the need for medical affairs to take the helm in defining and communicating the commercial value of healthcare innovations.
Health literacy is experiencing new challenges, and Medical Affairs is uniquely positioned to lead and partner with others in this space to ensure coordination, credibility and impact.
MEDICAL AFFAIRS: The Roles, Value and Practice of Medical Affairs in the Biopharmaceutical and Medical Technology Industries (Taylor & Francis, 2024)
This MAPS Executive Consortium article explores ways in which Medical Affairs can help industry adapt its practices to deal with emerging issues in the transition to personalized medicine.
Join the MAPS Med Tech FAWG as they discuss “Medical Affairs Mastery: Shaping the Future of MedTech with MAPS”!
The MAPS Executive Consortium details how Medical Affairs will drive the evolution of industry to match the needs of a changing society.
This White Paper draws on the expertise of 10 senior Medical Affairs leaders across diverse global organizations to describe the role of Medical Affairs in ensuring the MedTech industry meets the challenges of high-quality evidence, objective measures, changes in the healthcare landscape, and more.